A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

Exclusion Criteria

• •Participant has received prior chemotherapy for metastatic disease
• •Participant requiring major/minor surgery within 3 weeks prior to administration of the first dose of study treatment
• •Participant has received an investigational therapy within 4 weeks prior to study entry
• •Participant has known symptomatic brain metastases
• •Participant with non-measurable or assessable disease: exclusive blastic bone disease; pleural, pericardial or abdominal effusion as only evidence of disease
• •Participant in chronic daily treatment with corticosteroids (doses greater than \[\>\]10 milligrams per day \[mg/day\] of methylprednisolone or equivalent), except inhaled steroids
• •Pregnant or breastfeeding participant
• •Women of childbearing potential who are not using hormonal contraceptives or highly effective birth control during the study
• •Participant has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
• •Participant with significant renal, hematological or liver function alteration according to investigator's criteria
• •Participant has serious medical risk factors involving any of the major organ systems